CardioExchange Archive

During complementary presentations at the AHA, investigators provided new and updated study data from the BARI 2D trial.

Dr. Bernard Chaitman reported on findings regarding the secondary endpoints of cardiac death and myocardial infarction.  These findings suggest that patients similar to those in the PCI stratum benefit more from intensive medical therapy alone.  In contrast, patients with more extensive coronary disease, similar to those in the CABG stratum, benefited more from prompt revascularization via CABG along with intensive medical therapy and insulin sensitizing therapy.

Dr. Mark Hlatky reported results of a cost-effectiveness analysis suggesting that prompt revascularization overall increases cost among patients with type 2 diabetes and stable coronary disease.  In particular, intensive medical therapy with delayed revascularization, as needed, is more cost-effective and preferred for patients similar to those in the PCI arm.

The main findings of both the secondary endpoints and cost-effectiveness studies were published ahead of print in Circulation.